Urgent.News

What's breaking now, across thousands of outlets.

World

Access to Medicine Index: How Nigeria, Uganda, Kenya Face Gaps in Affordability, Availability of Essential Drugs

Despite progress in pharmaceutical research and access planning, patients in Nigeria, Uganda and Kenya continue to face significant barriers to affordable and reliable medicines, particularly for diabetes, cancer and other

The 2026 Access to Medicine Index reveals significant gaps in affordable and reliable access to essential medicines for patients in Nigeria, Uganda and Kenya. Despite progress in pharmaceutical research and access planning, patients in these countries continue to face barriers to accessing critical treatments, particularly for diabetes and cancer.

With 95% of projected diabetes growth expected in low- and middle-income countries, pharmaceutical companies have yet to make concrete commitments to ensure that newer treatments are affordable and available for Nigerian patients. While some companies have adopted lower-cost versions of existing GLP-1 and insulin products in other low-income markets, no such strategies have been identified for Nigeria.

To address these gaps, pharmaceutical companies should set clear, measurable and time-bound goals for patient reach, systematically measure and report progress, and hold themselves accountable for meeting these targets. However, despite pharmaceutical companies making access plans for drugs in the pipeline, these plans often focus on commercially attractive markets and lack clear commitments to make medicines affordable and available in low-income countries like Nigeria.

Key obstacles to translating access plans into actual availability and affordability include limited healthcare financing, fragmented regulatory and procurement systems, and gaps in health infrastructure. In Nigeria, economic conditions have also impacted pharmaceutical company operations, leading to some companies exiting the market altogether.

For essential medicines like insulin, continued access is crucial. Companies and governments must ensure affordable and reliable insulin supplies, prioritize underserved populations, strengthen local manufacturing, and improve monitoring and accountability.

Written by urgent.news from This Day's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at thisdaylive.com →

More in World

More from Thursday 19 November →